Skip to main content
Venkata K. Yellepeddi

Venkata K. Yellepeddi, PhD, RPh, DABCP

Languages spoken: English, Hindi, Telugu

Academic Information

Departments Primary - Pediatrics

Divisions: Clinical Pharmacology

Academic Office Information

venkata.yellepeddi@utah.edu

Board Certification

  • American Board of Clinical Pharmacology
  • National Association of Boards of Pharmacy

Research Interests

  • Pediatric formulations
  • Pediatric pharmacokinetic modeling
  • Nanotechnology for cancer diagnosis and treatment
  • Non-Viral Gene/Nucleic Acid Delivery
  • Pharmacokinetics of nanotechnology-based formulations
  • Oral Delivery
  • Formulation and stability studies for compounded formulations
  • Active learning strategies for teaching pharmaceutics and pharmacokinetics

Dr. Yellepeddi is Research Associate Professor in the Division of Clinical Pharmacology, Department of Pediatrics, University of Utah. Dr. Yellepeddi is an Adjunct Assistant Professor at the Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, University of Utah.

Dr. Yellepeddi’s research interests include the development of age-appropriate pediatric formulations and model informed pediatric drug development. He is currently working on research projects involving the development of a nasal formulation for the treatment of pediatric migraine and oral formulation for the postnatal therapy of cerebral palsy. His future research projects include Physiologically Based Pharmacokinetic (PBPK) modeling in pediatrics and development of in vitro models simulating microenvironments of various pediatric organs in normal and disease conditions. In addition, he is interested in the pharmacokinetics of nanotechnology-based therapeutics for the treatment of various disease conditions.

Dr. Yellepeddi is a licensed pharmacist in the State of Utah and advises pharmacists and pharmacy students on clinical pharmacology and compounding sterile and nonsterile dosage forms. Dr. Yellepeddi is a former chair of the American Association of Pharmaceutical Sciences, Rocky Mountain Discussion Group and item-writer for the National Association of Boards of Pharmacy (NABP). His teaching interests include drug development for medical students, basic and clinical pharmacokinetics, and formulation and drug delivery for pediatrics and adults.

Education History

Fellowship Division of Clinical Pharmacology, Department of Pediatrics, University of Utah
DABCP
Texas A&M Health Science Center
PhD
Research Fellow Indian Institute of Chemical Technology
Research Fellow
Kakatiya University
BPharm

Selected Publications

Journal Article

  1. M Azzeh, M Battaglia, S Davies, J Strauss, P Dogra, and Yellepeddi VK (). Physiologically based pharmacokinetic modeling to simulate amiloride pharmacokinetics following intranasal delivery. (Epub ahead of print) Int J Clin Pharmacol Ther.
  2. Yellepeddi VK, Lindley B, Radetich E, Kumar S, Bhakta Z, Leclair L, Parrot M, Young DC (2023). Population pharmacokinetics and target attainment analysis of vancomycin after intermittent dosing in adults with cystic fibrosis. Antimicrob Agents Chemother, 68(1), e0099223. (Read full article)
  3. Khurana N, Snner T, Hubbard O, Imburgia CE, Yellepeddi V, Ghandehari H, Watt KM (2023). Direct and continuous dosing of propofol can saturate Ex vivo ECMO circuit to improve propofol recovery. J Extra Corpor Technol, 55(4), 194-196. (Read full article)
  4. Shenkoya B, Yellepeddi V, Mark K, Gopalakrishnan M (2023). Predicting Maternal and Infant Tetrahydrocannabinol Exposure in Lactating Cannabis Users: A Physiologically Based Pharmacokinetic Modeling Approach. Pharmaceutics, 15(10). (Read full article)
  5. Salem AM, Smith T, Wilkes J, Bailly DK, Heyrend C, Profsky M, Yellepeddi VK, Gopalakrishnan M (2023). Pharmacokinetic Modeling Using Real-World Data to Optimize Unfractionated Heparin Dosing in Pediatric Patients on Extracorporeal Membrane Oxygenation and Evaluate Target Achievement-Clinical Outcomes Relationship. J Clin Pharmacol. (Read full article)
  6. Yellepeddi VK, Battaglia M, Davies SJC, Alt J, Ashby S, Shipman P, Anderson DJ, Rower JE, Reilly C, Voight M, Mim SR (2023). Pharmacokinetics of intranasal amiloride in healthy volunteers. Clin Transl Sci, 16(6), 1075-1084. (Read full article)
  7. Khurana N, Snner T, Hubbard O, Imburgia C, Stoddard GJ, Yellepeddi V, Ghandehari H, Watt KM (2023). Micellar Encapsulation of Propofol Reduces its Adsorption on Extracorporeal Membrane Oxygenator (ECMO) Circuit. AAPS J, 25(4), 52. (Read full article)
  8. Constance JE, McFarland MM, Casucci T, Deininger MW, Enioutina EY, Job K, Lemons RS, Lim CS, Ward RM, Yellepeddi V, Watt KM (2023). Mapping the Evidence for Opioid-Mediated Changes in Malignancy and Chemotherapeutic Efficacy: Protocol for a Scoping Review. JMIR Res Protoc, 12, e38167. (Read full article)
  9. Dos Santos HT, Nam K, Gil D, Yellepeddi V, Baker OJ (2023).   Current experimental methods to investigate the impact of specialized pro-resolving lipid mediators on Sjögren's syndrome. Front Immunol.
  10. Azzeh M, Battaglia M, Davies S, Strauss J, Dogra P, Yellepeddi V (2022). Novel intranasal treatment for anxiety disorders using amiloride, an acid-sensing ion channel antagonist: Pharmacokinetic modeling and simulation. Int J Clin Pharmacol Ther, 60(6), 253-263. (Read full article)
  11. Yellepeddi VK, Odeti S (2021).   Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients. Am Fam Physician, 104(3), 311-312.
  12. Odeti S, Yellepeddi VK (2021). Remdesivir (Veklury) for the Treatment of COVID-19 in Hospitalized Patients. Am Fam Physician, 104(3), 311-312. (Read full article)
  13. Yellepeddi VK, Parashar K, Dean SM, Watt KM, Constance JE, Baker OJ (2020). Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically-Based Pharmacokinetic Modeling. Clin Transl Sci, 14(2), 683-691. (Read full article)
  14. Dogra P, Ruiz-Ramrez J, Sinha K, Butner JD, Pelez MJ, Rawat M, Yellepeddi VK, Pasqualini R, Arap W, Sostman HD, Cristini V, Wang Z (2020).   Innate Immunity Plays a Key Role in Controlling Viral Load in COVID-19: Mechanistic Insights from a Whole-Body Infection Dynamics Model. 4(1), 248-265.
  15. Dogra P, Ruiz-Ramrez J, Sinha K, Butner JD, Pelez MJ, Rawat M, Yellepeddi VK, Pasqualini R, Arap W, Sostman HD, Cristini V, Wang Z (2020). Innate Immunity Plays a Key Role in Controlling Viral Load in COVID-19: Mechanistic Insights from a Whole-Body Infection Dynamics Model. ACS Pharmacol Transl Sci, 4(1), 248-265. (Read full article)
  16. Bolla PK, Gote V, Singh M, Yellepeddi VK, Patel M, Pal D, Gong X, Sambalingam D, Renukuntla J (2020). Preparation and characterization of lutein loaded folate conjugated polymeric nanoparticles. J Microencapsul, 37(7), 502-516. (Read full article)
  17. Biltaji E, Enioutina EY, Yellepeddi V, Rower JE, Sherwin CMT, Ward RM, Lemons RS, Constance JE (2020). Supportive care medications coinciding with chemotherapy among children with hematologic malignancy. Leuk Lymphoma, 61(8), 1920-1931. (Read full article)
  18. Rower JE, King AD, Wilkins D, Wilkes J, Yellepeddi V, Maese L, Lemons RS, Constance JE (2020). Dronabinol Prescribing and Exposure Among Children and Young Adults Diagnosed with Cancer. J Adolesc Young Adult Oncol, 10(2), 175-184. (Read full article)
  19. Yellepeddi V, Sayre C, Burrows A, Watt K, Davies S, Strauss J, Battaglia M (2020). Stability of extemporaneously compounded amiloride nasal spray. PLoS One, 15(7), e0232435. (Read full article)
  20. Yellepeddi VK, Baker OJ (2019). Predictive modeling of aspirin-triggered resolvin D1 pharmacokinetics for the study of Sjögren's syndrome. Clin Exp Dent Res, 6(2), 225-235. (Read full article)
  21. Bolla PK, Meraz CA, Rodriguez VA, Deaguero I, Singh M, Yellepeddi VK, Renukuntla J (2019). Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies. Molecules, 24(17). (Read full article)
  22. Burrows AC, Yellepeddi VK, Snyder S, Wakefield M, Jackson D, Huynh J, Nguyen K, Sayre CL (2019). Development and Validation of a Stability-indicating High-performance Liquid Chromatographic Method for Quantification of Progesterone in Compounded Glycerinated Gelatin Troches. Int J Pharm Compd, 23(4), 340-350. (Read full article)
  23. Sayre CL, Cox C, Velazquez G, Le MT, Nguyen AH, Ramos M, Burrows A, Yellepeddi VK (2019). Chemical Stability of Progesterone in Compounded Oral Rapid-dissolving Tablets. Int J Pharm Compd, 23(1), 62-64. (Read full article)

Review

  1. Sayre CL, Yellepeddi VK, Job KM, Krepkova LV, Sherwin CMT, Enioutina EY (2023).  Current use of complementary and conventional medicine for treatment of pediatric patients with gastrointestinal disorders. [Review]. Front Pharmacol.
  2. Sayre CL, Yellepeddi VK, Job KM, Krepkova LV, Sherwin CMT, Enioutina EY (2023). Current use of complementary and conventional medicine for treatment of pediatric patients with gastrointestinal disorders. [Review]. Front Pharmacol, 14, 1051442. (Read full article)
  3. Dos Santos HT, Nam K, Gil D, Yellepeddi V, Baker OJ (2023). Current experimental methods to investigate the impact of specialized pro-resolving lipid mediators on Sjögren's syndrome. [Review]. Front Immunol, 13, 1094278. (Read full article)
  4. Yellepeddi VK, Joseph A, Nance E (2019). Pharmacokinetics of Nanotechnology-Based Formulations in Pediatric Populations. [Review]. Adv Drug Deliv Rev, (151-152), 44-45.

Book Chapter

  1. Vadlapatla R, Gayakwad S, Yellepeddi VK, Wong EY (2020). Needle-free injectors. In Eric Chappel (Ed.), Drug Delivery Devices and Therapeutic Systems (pp. 199-210). London, United Kingdom: Academic Press.
  2. Yellepeddi VK, Roberts JK, Escobar L, Sayre C, Sherwin CM (2018). The Relationship Between Pharmacogenomics and Pharmacokinetics and Its Impact on Drug Choice and Dosing Regimens in Pediatrics. In Alan Talevi, Pablo A. M. Quiroga (Eds.), ADME Processes in Pharmaceutical Sciences (1st Edition, pp. 203-222). Switzerland: Springer Nature.

Conference Proceedings

  1. Yellepeddi VK, Sherwin CMT (2018). Model-based Dose Individualization Approaches Using Biomarkers. Montreux, Switzerland: Population Approach Group Europe.

Abstract

  1. Yellepeddi VK, Azzeh M, Davies S, Strauss J, Battaglia M (2020). Physiologically‐based Pharmacokinetic Model to Predict Amiloride Pharmacokinetics After Intranasal Administration [Abstract]. 9(S2), 47-47.
  2. Yellepeddi VK, Wagstaff JS, Constance JE (2019). A Physiologically-based Pharmacokinetic Model for Intravenous Voriconazole in Pediatric Patients With and Without Cancer [Abstract]. 8(S1), 85-85.
  3. Yellepeddi VK, Mohammadpour R, Sayre C, Khambampati SP, Mishra MK, Kannan R, Ghandehari H (09/12/2018). Oral permeability and pharmacokinetics of a pediatric formulation for the treatment of cerebral palsy [Abstract].
  4. Dichwalkar T, Bapat S, Pancholi P, Yellepeddi VK, Sehdev V (2016). Omega-3 fatty acid conjugated paclitaxel dendrimers exhibit enhanced anticancer activity in various preclinical models of gastrointestinal cancers; also presented as a poster at the American Association of Cancer Research 107th Annual Meeting, New Orleans, LA [Abstract]. Cancer Research, 76(14 Supplement), 2200.
  5. Yellepeddi VK, Radhakrishnan J, Radhakrishnan R (2016). Comparative Evaluation of Prostate Tissue Distribution Profiles of Four Non-Steroidal Anti-inflammatory Drugs in Rats; also presented as a poster at the American Pain Society Annual Meeting, Palm Springs, CA [Abstract]. The Journal of Pain, 17(4), S70.
  6. Dichwalkar TYellepeddi VK, Sehdev V (2015). Omega-3 Fatty Acid Conjugated Dendrimers for Delivery of Paclitaxel to Gastroesophageal and Pancreatic Cancers [Abstract].
  7. Vo A, Phan J, Dorigatti J, Talbot J, Yellepeddi VK (2015). Gastrointestinal stability and oral permeability of a novel rapid-acting antidepressant, Ro25-6981; also presented as a poster at the American College of Clinical Pharmacy (ACCP) Global Conference, San Francisco, CA [Abstract]. Pharmacotherapy: The Journal Of Human Pharmacology And Drug Therapy, 35(11), e318.
  8. Phan J, Vo A, Dorigatti J, Talbot J, Yellepeddi VK (2015). Development and validation of a rapid high-performance liquid chromatography (HPLC) method for the quantification of a rapid-acting antidepressant, Ro 25-6981 in various biological matrices; also presented as a poster at the American College of Clinical Pharmacy (ACCP) Global Conference, San Francisco, CA [Abstract]. Pharmacotherapy: The Journal Of Human Pharmacology And Drug Therapy, 35(11), e318.
  9. Mandal M, Yellepeddi VK (2015). Knowledge Retention of Biomedical Sciences (Immunology) Course [Abstract].
  10. Yellepeddi VK, Radhakrishnan J (2014). Formulation and chemical stability Studies of a preservative-free prochlorperazine nasal Spray for pain relief in migraine. [Abstract].
  11. Yellepeddi VK, Kim K, Radhakrishnan J (2014). Omega-3 fatty acid conjugated dendrimers for delivery of paclitaxel to multidrug-resistant ovarian cancer. [Abstract].
  12. Yellepeddi VK, Kim K, Radhakrishnan J (2014). Omega-3 fatty acid conjugated dendrimers for delivery of paclitaxel to multidrug-resistant ovarian cancer; also presented as a poster at the American Association of College of Pharmacy (AACP) Annual Meeting, Grapevine, TX [Abstract]. American Journal of Pharmaceutical Education, 78(5), 111; pg 136.
  13. Yellepeddi VK, Nielson R, Chennamaneni SR (2013). Development of Dequalinium coated poly (D,L-lactide-co-glycolide) nanoparticles for paclitaxel delivery [Abstract].
  14. Yellepeddi VK, Kumar A, Vangara K, Palakurthi S (2010). Sensitizing drug resistant ovarian cancer cells to cisplatin therapy using surface modified PAMAM dendrimers [Abstract].
  15. Yellepeddi VK, Kumar A, Palakurthi S (2009). Dendritic cisplatin as a nanodevice for treatment of ovarian cancer. [Abstract].
  16. Yellepeddi VK, Kumar A, Palakurthi S (2008). Biotinylated Cisplatin-loaded PAMAM dendrimers for chemotherapy of ovarian cancer [Abstract].
  17. Kumar A, Yellepeddi VK, Palakurthi S (2008). Surface-modified polyamidoamine (PAMAM) dendrimers for sitespecific gene delivery [Abstract].
  18. Yellepeddi VK, Kumar A, Hildreth MB, Palakurthi S (2007). Cellular uptake studies of biotinylated PAMAM dendrimers in ovarian cancer cells in vitro. [Abstract].

Patent

  1. Venkata Kashyap Yellepeddi (2018). Preservative-free prochlorperazine nasal spray for migraine therapy. U.S. Patent No. US 10,617,682 B2. Washington, D.C.:U.S. Patent and Trademark Office.